Hjem › Glioblastom › Ohio
Glioblastom kliniske forsøg i Ohio
23 studier for Glioblastom søger deltagere på steder i Ohio.
Byer i Ohio
Officiel studietekst (engelsk)
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University Hospitals Cleveland Medical Center*, Cleveland
- Cleveland Clinic, Cleveland
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT03970447Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Neurological Institute Brain Tumor Centre Taussig Cancer Cente, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT05902169Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Cleveland Clinic Taussig Cancer Center, Cleveland
- Ohio State University, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07326566Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- The Ohio State University, Columbus
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07195591Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
- Case Western Reserve University, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT07452458hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT05052957Targeted Pediatric High-Grade Glioma Therapy
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererObservationsstudie
12 Months – 39 Years · Alle køn · Opdateret 8. sep. 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererFase 2
Alder 12 til 39 · Alle køn · Opdateret 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Cleveland Clinic, Cleveland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT05303519Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT05565118A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07003542Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- Ohio State University Medical Center, Columbus
Rekrutterer
Alder 18 til 85 · Alle køn · Opdateret 21. jul. 2026 · NCT06910306Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Ohio State University, Columbus
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 17. jul. 2026 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- The Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. jul. 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererTidlig fase 1Frivillige med god helbredstilstand velkomne
Alder 1 til 21 · Alle køn · Opdateret 29. jun. 2026 · NCT06333899Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
- Ohio State University Hospital, Columbus
RekruttererFase 1/2
Alder 18 til 70 · Alle køn · Opdateret 12. jun. 2026 · NCT07346144Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
RekruttererFase 2
12 Months – 39 Years · Alle køn · Opdateret 29. maj 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Ohio State University Comprehensive Cancer Center, Columbus
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT06810544Sacituzumab Govitecan in Recurrent Glioblastoma
- Cleveland Clinic Taussig Cancer Center, Cleveland
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. mar. 2026 · NCT04559230SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- The Cleveland Clinic, Cleveland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. jun. 2025 · NCT05879367Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.